Array reports updated data for encorafenib/binimetinib/Erbitux in metastatic CRC

Array BioPharma Inc. (NASDAQ:ARRY) reported updated response data for a combination regimen of encorafenib (LGX818), binimetinib (MEK162) and Erbitux cetuximab in the safety lead-in portion of the Phase III BEACON CRC trial to treat BRAF V600E-mutant metastatic colorectal cancer after one or two prior lines of therapy. The company presented data at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Data from 29 patients at a median follow-up of 7.9 months in the open-label, international trial’s safety lead-in portion showed the combination led to a confirmed objective response rate (ORR) of 48% overall, including three complete responses and 11 partial responses, plus 13 cases of stable disease. The median duration of response was 5.4 months. All but one of 28 evaluable patients had tumor regressions. The preliminary progression-free survival (PFS) estimate is 8 months. The ORR was 62%, including two complete responses and eight partial responses, in patients who previously had one line of therapy and 31%, including one complete response and three partial responses, in patients with two prior lines of therapy. The PFS was 7.6 and 8.1 months in patients who had one or two previous treatments, respectively...